The current status of immunobased therapies for metastatic renal-cell carcinoma

The management of metastatic renal-cell carcinoma (mRCC) represents an important clinical challenge. Since being approved in the early 1990s, aspecific immunotherapy has been a mainstay of treatment for mRCC and the only therapy that has demonstrated long-term cures for mRCC. However, in recent time...

Descripción completa

Detalles Bibliográficos
Autores principales: Sathianathen, Niranjan J, Krishna, Suprita, Anderson, J Kyle, Weight, Christopher J, Gupta, Shilpa, Konety, Badrinath R, Griffith, Thomas S
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723125/
https://www.ncbi.nlm.nih.gov/pubmed/29255699
http://dx.doi.org/10.2147/ITT.S134850

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5723125/
https://www.ncbi.nlm.nih.gov/pubmed/29255699
http://dx.doi.org/10.2147/ITT.S134850

Ejemplares similares